INTRODUCTION
I-cell disease and pseudo-Hurler polydystrophy (mucolipidoses II and III) comprise a heterogeneous group of autosomal recessive disorders of lysosomal protein processing and targeting, caused by deficiency of the enzyme UDP-N-acetylglucosamine: lysosomal protein precursor N-acetylglucosamine 1-phosphotransferase (GlcNAc-PO4 transferase; EC 2.7.8.17) (Hasilik et al., 1981; . When an absence or a deficiency of this enzyme activity occurs, high-mannosetype oligosaccharides of lysosomal protein precursors are not phosphorylated. This results in their conversion into complex or hybrid-type oligosaccharides, and the lysosomal protein precursors are secreted from the cells rather than targeted into lysosomes (Neufeld & McKusick, 1983) .
The heterogeneity within I-cell disease and pseudoHurler polydystrophy has previously been demonstrated biochemically by different patterns of intracellular and extracellular lysosomal enzyme activities of cultured skin fibroblasts , as well as by qualitative and quantitative differences in the electrophoretic mobilities and lectin-binding properties of these altered lysosomal enzymes, and in their responsiveness to sucrose loading (Okada et al., 1983) . Varki et al. (1981) , using a-methyl mannoside as an acceptor in the assay of N-acetylglucosamine I-phosphotransferase, have shown that fibroblasts from patients with the classical form of pseudo-Hurler polydystrophy had higher residual activities than those from patients with I-cell disease. They have also identified a variant form of pseudo-Hurler polydystrophy in which the mutant enzyme demonstrated deficiency only toward lysosomal enzyme acceptors while retaining normal activity toward a-methyl mannoside. The apparent Km values of this mutant enzyme toward oc-methyl mannoside, high-mannose-type oligosaccharides and UDPGlcNAc were normal. Complementation studies by Shows et al. (1982 ) and Mueller et al. (1983 have indicated the presence of two subgroups in Icell disease and three distinct complementation groups among patients with pseudo-Hurler polydystrophy. The first complementation group (A) was identical with I-cell disease; the second group (B). consisted of a single cell line; and the third (C) included the variant form described by Varki et al. (1981) . The mutant enzymes of the two major complementation groups (A and C) differed from each other by the optimum temperature of the enzymic activity (Little et al., 1986) and by the susceptibility of the phosphorylation of mono-and oligo-saccharide acceptors to inhibition by lysosomal enzyme preparations (Little et al., 1986; Ben-Yoseph et al., 1986a) .
In the present study we Lang & Kornfeld (1984) . Hexosaminidases A and B were purified from human placenta by affinity chromatography as previously described (Geiger et al., 1974) , and monitored with 4-methylumbelliferyl derivatives of ,3-N-acetylglucosamine 6-sulphate (Ben-Yoseph et al., 1985) and /J-N-acetylglucosamine (Sigma), respectively.
Cell lines
Cultured skin fibroblasts from patients with I-cell disease and pseudo-Hurler polydystrophy, and from apparently normal subjects, were obtained, maintained and harvested as previously described (Ben-Yoseph et al., 1983) . Cell lines with the prefix GM were obtained from the NIGMS Human Genetic Mutant Cell Repository (Camden, NJ, U.S.A.). Preparation of Golgi-rich membranes Cell pellets were homogenized in 4 vol. of 0.25 Msucrose containing 10 mM-Tris/HCl buffer, pH 7.4, 1 mM-iodoacetamide and 1 mM-leupeptin, by eight strokes in a Con-Torque homogenizer. Golgi-rich membranes were isolated by the method of Sandberg et al. (1980) using a sucrose density gradient. The Golgi membrane fraction obtained from the gradient was diluted to 0.25 M-sucrose, and the membranes were pelleted by centrifugation at 105000 g for 90 min and washed twice in 0.25 M-sucrose/0.25 M-NaCl. Protein was determined by the dye-binding method of Bradford (1976) using bovine y-globulin as standard.
Radiation inactivation
Golgi membrane preparations were suspended in water by homogenization, and portions containing 1 mg of protein/ml were freeze-dried in 1.5 ml Eppendorf micro test tubes. The test tubes containing the freezedried material were flushed with N2, capped, and irradiated at 38°C in a 60Co irradiator at a dose rate of about 2 Mrad/h (Gammacell model 220, Atomic Energy of Canada) as described previously (Beauregard & Potier, 1982; Beauregard et al., 1983) . The freeze-dried samples were kept on solid CO2 or at -20°C except for the time of the radiation inactivation experiments. After exposure to radiation for various periods of time, the samples were resuspended in 1 % (v/v) Triton X-100 and assayed for enzyme activities. Non-irradiated samples retained more than 90 % of their initial enzyme activities. The relative molecular size was calculated according to the equation: log(Molecular size) = 5.89-logD37t(°C) -0.0028t (OC) which is valid at any temperature t between -200 and + 200 'C (Beauregard & Potier, 1984) . D37,t is the radiation dose (in Mrad) that inactivates the enzyme to 37 % of its initial activity. Control enzyme preparations of measured D37,t values and known molecular sizes were used for calibration of the 60Co source (Beauregard & Potier, 1982 10 mM-MgCl2, 5 mM-dimercaptopropanol, 10 mM-CDPcholine, 2 mM-ADP and 0.125 mM-leupeptin. Following incubation for 60 min at 37°C, the reaction was terminated, the glycoprotein fraction was digested by Pronase and the phosphorylated high-mannose glycopeptides were isolated by affinity chromatography on immobilized concanavalin A and quantified as described . Activity toward z-methyl mannoside acceptor was assayed by a modification of previously described methods Waheed et al., 1982; Ben-Yoseph et al., 1984 , 1986b . The composition of the reaction mixture was as described above, except for UDP-[1-'4C]GlcNAc (35 mCi/mmol) replacing [l-32P]UDP-GlcNAc, and 5 ,umol of a-methyl mannoside replacing lysosomal enzyme preparation. Following incubation for 30 or 60 min at 37°C, the reaction was terminated, the phosphodiester product of the transfer reaction ([1-_4C]GlcNAca-l-phospho-6-ac-l-methylmannose) was separated from the breakdown product ([1-_4C]GlcNAc) on a QAESephadex column (0.5 cm x 5.0 cm) and quantified as described (Ben-Yoseph et al., 1984) . Specific activities of GlcNAc-PO4 transferase were expressed as pmol of GlcNAc-1-phosphate transferred/h per mg of cell protein.
RESULTS
Residual GlcNAc-PO4 transferase activity in mutant cell lines Cultured skin fibroblasts from the various patients with I-cell disease and pseudo-Hurler polydystrophy, and from normal controls, were assayed for GlcNAc-P04 transferase activity toward natural and artificial acceptor substrates (Table 1) . Endogenous glycoproteins and exogenously-added hexosaminidase preparations served as natural acceptors, and the monosaccharide a-methyl mannoside served as an artificial acceptor. All the mutant cell lines examined demonstrated severe deficiency of GlcNAc-PO4 transferase activity toward natural acceptor substrates. The low levels of these residual activities were found to be insufficient for assessment of the molecular size of the mutant enzyme by the radiation-inactivation method. Higher residual activities were determined in cell lines from patients with I-cell disease and classical pseudo-Hurler polydystrophy N-Acetylglucosamine 1 -phosphotransferase size in I-cell disease Table 1 . GIcNAc-PO4 transferase activities in normal and mutant cell ines The activities toward natural (endogenous glycoprotein and exogenously-added hexosaminidase A preparation) and artificial (a-methyl mannoside) acceptor substrates were assayed in whole sonicates of cultured skin fibroblasts or in Golgi-rich membrane fractions as described in the Materials and methods section. Abbreviation: ND, not determined. Fig. 1 as slopes of linear regression plots. The rate of inactivation of this activity in enzyme preparation from I-cell-disease fibroblasts was significantly lower (P < 0.01) than that of the normal but essentially indistinguishable from that of classical pseudo-Hurler polydystrophy fibroblasts. This indicated a smaller target size for the mutant GlcNAc-PO4 transferase in the classical forms of both disorders. In contrast, molecuilar sizes larger than the normal were found for the mutant enzyme in cell lines from patients with the variant forms of pseudo-Hurler polydystrophy. This was indicated by rates of inactivation which were significantly higher (P < 0.01) than that ofthe normal enzyme activity. The extent of the increased decay of enzyme activity as a function of the radiation dose was about 1.4 times the normal in cell lines from patients of two unrelated families (variant pseudo-Hurler polydystrophy 1), and about 2.1 times the normal in cell lines from patients of a third family (variant pseudo-Hurler polydystrophy II). This suggests a heterogeneity within the variants' complementation group. D37,38 values (the radiation dose that inactivates the enzyme to 37 % of its initial activity at 38°C) and the molecular sizes of the normal and mutant GlcNAc-PO4 transferases (Table 2) were obtained from the rate of inactivation of a-methyl mannoside phosphorylation, and thus reflect the minimal size of enzymic protein that is necessary for carrying out this reaction or destructive energy transfer between associated subunits (Beauregard et al., 1987) . The molecular size of the mutant enzyme in I-cell disease and classical pseudo-Hurler-polydystrophy cell lines was about two-thirds of the normal size, and those of pseudo-Hurler polydystrophy variants I and II were about 1.4 and 2.1 times the normal, respectively. These findings suggest that an enzyme component that is normally involved in the catalytic function may be altered or missing in the classical forms of these disorders, and that the mutations responsible for the variant forms probably cause aggregation of the enzyme which does not affect its catalytic activity but interferes with its binding to the natural lysosomal glycoprotein substrates. Hurler-polydystrophy fibroblasts were essentially identical to each other but significantly smaller than that of the normal enzyme, whereas those of variant cell lines were significantly larger than the normal. The difference in the extent of the increased molecular size among cell lines of the latter group is probably the result of allelic mutations occurring within the locus responsible for this complementation group. Molecular size changes were also observed in Gaucher disease by using the same technique (Maret et al., 1983; Choy et al., 1986) . The observed molecular size alterations suggest that the mutations responsible for the classical forms cause a reduction in the size of GlcNAc-PO4 transferase, which may be due to a missing enzyme component, improper processing or increased susceptibility to proteolysis. These mutations render the enzyme catalytically inefficient toward both natural and artificial acceptor substrates and thus may be localized to a catalytic subunit. In contrast, the mutations responsible for the variant forms probably cause aggregation of the enzyme, which does not affect its catalytic activity toward artificial substrates. The mutant enzyme in this group of patients is incapable of binding natural acceptor substrate, and these mutations are probably occurring at a gene that encodes a lysosomal protein-recognizing subunit.
DISCUSSION

